Seeking Alpha
 

Ono Pharmaceutical Co., Ltd. (OPHLF)

- Grey Market
  • Dec. 19, 2014, 11:19 AM
    • Gilead Sciences (GILD +1.1%) and Osaka, Japan-based Ono Pharmaceutical Company (OTC:OPHLF) (OTCPK:OPHLY) enter into an exclusive license agreement to develop and commercialize ONO-4059, Ono's oral Brutons tyrosine kinase (BTK) inhibitor, for the treatment of B-cell malignancies and other diseases.
    • Under the terms of the agreement, Gilead will pay Ono an upfront fee plus development, regulatory and commercial milestones.
    • Gilead will have exclusive rights to develop and commercialize ONO-4059 worldwide except Japan, South Korea, Taiwan, China and the ASEAN countries, where Ono retains development and commercialization rights.
    | 19 Comments
Visit Seeking Alpha's
OPHLF vs. ETF Alternatives
Company Description
Production, purchase and sale of pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals
Sector: Healthcare
Country: Japan